Assessment of 17 clinically available renal biomarkers to predict acute kidney injury in critically ill patients

Abstract

Apart from CysC, the combination of most clinically available biomarkers or clinical markers does not significantly improve the forecasting ability, and the cost-benefit ratio is not economical.